Alliance Foundation Trials LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$10,227,601	36
2024	Research	$9,231,470	63
2023	Research	$15,423,660	91
2022	Research	$34,594,009	118
2021	Research	$37,977,282	97
2020	Research	$15,092,342	72
2019	Research	$6,864,283	59

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $106,415,596 233 payments
Janssen Research & Development, LLC $19,865,367 297 payments
AstraZeneca Pharmaceuticals LP $2,653,420 5 payments
Pharmacyclics LLC, An AbbVie Company $476,263 1 payment

Studies the money was for Research payments · program years 2019–2025

Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for HR Or Her2 Early Breast Cance $63,051,277 78 payments
Patinaa Randomized Open Label Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib Antiher2 Therapy Endocrine Therapy VS Antiher2 Therapy Endocrine Therapy After Induction Treatment for Hrher2 Metastatic Breast Cancer $29,104,795 88 payments
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer $17,755,301 177 payments
Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for HR Or Her2 Early Breast Cancer Wi203696 $8,847,992 31 payments
CRC Pallas Palbociclib Collaborative Adjuvant Studya Randomized Phase 3 Trial of Palbociclib With Adjuvant Endocrine Therapy Versus Endocrine Therapy Alone for Hormone Receptor Positive Her2negative Breast Cancer $2,316,995 7 payments
CHIO3 Trial Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable stage IIIA Non Small Cell Lung Cancer $2,076,933 4 payments
A Phase II Study of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma $1,662,812 90 payments
Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for HR Or Her2 Early Breast Cancer $1,410,814 9 payments
A Phase II Study of Palbociclib in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma $753,975 8 payments
A Phase III Randomized Open Label Trailo to Evaluate the Efficacy and Safety of Palbociclib Antiher2 Therapy Endocrine Therapy VS Antiher2 Therapy Endocrine Therapy After Induction Treatment for Hormone Reception Positive Hrher2 Positive Metastatic Breast Cancer Mbc1 $706,348 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.